Imperial College London
Portrait Picture

ProfessorIainMcNeish

Faculty of Medicine, Department of Surgery & Cancer

Chair in Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2185i.mcneish Website

 
 
//

Assistant

 

Ms Sophie Lions +44 (0)20 7594 2792

 
//

Location

 

G036Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Swisher:2021:10.1038/s41467-021-22582-6,
author = {Swisher, EM and Kwan, TT and Oza, AM and Tinnker, AV and Ray-Coquard, I and Oaknin, A and Coleman, RL and Aghajanian, C and Konecny, GE and O'Malley, DM and Leary, A and Provencher, D and Welch, S and Chen, L-M and Wahner, Hendrickson AE and Ma, L and Ghatage, P and Kristeleit, RS and Dorigo, O and Musafer, A and Kaufmann, SH and Elvin, JA and Lin, DI and Chambers, SK and Dominy, E and Vo, L-T and Goble, S and Maloney, L and Giordano, H and Harding, T and Dobrovic, A and Scott, CL and Lin, KK and McNeish, I},
doi = {10.1038/s41467-021-22582-6},
journal = {Nature Communications},
title = {Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)},
url = {http://dx.doi.org/10.1038/s41467-021-22582-6},
volume = {12},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and RAD51D mutations and high-level BRCA1 promoter methylation predict response to rucaparib, similar to BRCA1/BRCA2 mutations. BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi. Genomic scars associated with homologous recombination deficiency are irreversible, persisting even as platinum resistance develops, and therefore are predictive of rucaparib response only in platinum-sensitive disease. The RAS, AKT, and cell cycle pathways may be additional modulators of PARPi sensitivity.
AU  - Swisher,EM
AU  - Kwan,TT
AU  - Oza,AM
AU  - Tinnker,AV
AU  - Ray-Coquard,I
AU  - Oaknin,A
AU  - Coleman,RL
AU  - Aghajanian,C
AU  - Konecny,GE
AU  - O'Malley,DM
AU  - Leary,A
AU  - Provencher,D
AU  - Welch,S
AU  - Chen,L-M
AU  - Wahner,Hendrickson AE
AU  - Ma,L
AU  - Ghatage,P
AU  - Kristeleit,RS
AU  - Dorigo,O
AU  - Musafer,A
AU  - Kaufmann,SH
AU  - Elvin,JA
AU  - Lin,DI
AU  - Chambers,SK
AU  - Dominy,E
AU  - Vo,L-T
AU  - Goble,S
AU  - Maloney,L
AU  - Giordano,H
AU  - Harding,T
AU  - Dobrovic,A
AU  - Scott,CL
AU  - Lin,KK
AU  - McNeish,I
DO  - 10.1038/s41467-021-22582-6
PY  - 2021///
SN  - 2041-1723
TI  - Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
T2  - Nature Communications
UR  - http://dx.doi.org/10.1038/s41467-021-22582-6
UR  - http://hdl.handle.net/10044/1/88649
VL  - 12
ER  -
Download